IOVA Q3 2024 Earnings — Iovance Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena

IOVAIovance Biotherapeutics, Inc.

$2B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$59M+12384.9% YoY

Gross Profit

$19M32.0% margin

Operating Income

-$89M-152.1% margin

Net Income

-$84M-142.7% margin

EPS (Diluted)

$-0.28

QoQ Revenue Growth

+88.2%

Cash Flow

Operating Cash Flow

-$59M

Free Cash Flow

-$61M

Stock-Based Comp.

$31M

Balance Sheet

Total Assets

$991M

Total Liabilities

$218M

Stockholders' Equity

$773M

Cash & Equivalents

$164M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$59M	$469,000	+12384.9%
Gross Profit	$19M	-$4M	+583.9%
Operating Income	-$89M	-$118M	+24.8%
Net Income	-$84M	-$114M	+26.6%

Geographic Segments

UNITED STATES

$58M99%

Non-US

$740,0001%